|
|
Volumn 338, Issue , 2009, Pages
|
|
NICE recommends kidney cancer drug it previously rejected on cost grounds.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
INDOLE DERIVATIVE;
PYRROLE DERIVATIVE;
SUNITINIB;
COST BENEFIT ANALYSIS;
DRUG APPROVAL;
DRUG COST;
ECONOMICS;
HUMAN;
KIDNEY TUMOR;
NOTE;
QUALITY ADJUSTED LIFE YEAR;
UNITED KINGDOM;
ANTINEOPLASTIC AGENTS;
COST-BENEFIT ANALYSIS;
DRUG APPROVAL;
DRUG COSTS;
GREAT BRITAIN;
HUMANS;
INDOLES;
KIDNEY NEOPLASMS;
PYRROLES;
QUALITY-ADJUSTED LIFE YEARS;
|
|
EID: 60849125148
PISSN: None
EISSN: 14685833
Source Type: Journal
DOI: 10.1136/bmj.b499 Document Type: Note |
|
Times cited : (8)
|
|
References (0)
|
